Shipo Wu

2.8k total citations · 1 hit paper
38 papers, 1.2k citations indexed

About

Shipo Wu is a scholar working on Infectious Diseases, Epidemiology and Genetics. According to data from OpenAlex, Shipo Wu has authored 38 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Infectious Diseases, 14 papers in Epidemiology and 14 papers in Genetics. Recurrent topics in Shipo Wu's work include Virus-based gene therapy research (14 papers), Viral Infections and Outbreaks Research (11 papers) and SARS-CoV-2 and COVID-19 Research (10 papers). Shipo Wu is often cited by papers focused on Virus-based gene therapy research (14 papers), Viral Infections and Outbreaks Research (11 papers) and SARS-CoV-2 and COVID-19 Research (10 papers). Shipo Wu collaborates with scholars based in China, Czechia and United States. Shipo Wu's co-authors include Lihua Hou, Wei Chen, Xiaohong Song, Busen Wang, Zhe Zhang, Tao Zhu, Qiang Guo, Jinlong Zhang, Jingxin Li and Fengcai Zhu and has published in prestigious journals such as The Lancet, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Shipo Wu

37 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

2021 192 citations Shipo Wu, Jianying Huang et al. The Lancet Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shipo Wu China	16	699	335	259	200	191	38	1.2k
Lihua Hou China	13	519 0.7×	301 0.9×	184 0.7×	173 0.9×	148 0.8×	38	1.0k
Pavitra Roychoudhury United States	23	973 1.4×	481 1.4×	461 1.8×	168 0.8×	228 1.2×	64	1.7k
Edith Jasny Germany	13	536 0.8×	406 1.2×	193 0.7×	73 0.4×	412 2.2×	20	1.1k
Benjamin Petsch Germany	18	1.0k 1.4×	1.1k 3.4×	257 1.0×	237 1.2×	547 2.9×	33	2.0k
Pamela Österlund Finland	22	589 0.8×	266 0.8×	633 2.4×	61 0.3×	693 3.6×	51	1.6k
Scott Preiss Australia	14	220 0.3×	337 1.0×	365 1.4×	123 0.6×	352 1.8×	22	1.0k
Annalisa Ciabattini Italy	20	625 0.9×	491 1.5×	231 0.9×	137 0.7×	578 3.0×	50	1.6k
David J. Dowling United States	24	364 0.5×	353 1.1×	457 1.8×	67 0.3×	994 5.2×	56	1.9k
Daniela Damjanovic Canada	19	522 0.7×	315 0.9×	503 1.9×	152 0.8×	913 4.8×	26	1.5k
Xiling Guo China	20	971 1.4×	341 1.0×	168 0.6×	43 0.2×	113 0.6×	39	1.5k

Countries citing papers authored by Shipo Wu

Since Specialization

Citations

This map shows the geographic impact of Shipo Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shipo Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shipo Wu more than expected).

Fields of papers citing papers by Shipo Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shipo Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shipo Wu. The network helps show where Shipo Wu may publish in the future.

Co-authorship network of co-authors of Shipo Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Shipo Wu. A scholar is included among the top collaborators of Shipo Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shipo Wu. Shipo Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Busen, Zhenghao Zhao, Shipo Wu, et al.. (2025). Development of a novel adenovirus type 4 vector as a promising respiratory vaccine vehicle. Frontiers in Immunology. 16. 1572081–1572081. 1 indexed citations

Wu, Shipo, et al.. (2025). Engineered Exosome‐Based Senolytic Therapy Alleviates Stroke by Targeting p21⁺CD86⁺ Microglia. Exploration. 5(3). 20240349–20240349. 8 indexed citations

Zhang, Jinlong, Hao Ma, Yao Li, et al.. (2024). Microparticulated Polygonatum sibiricum polysaccharide shows potent vaccine adjuvant effect. International Journal of Pharmaceutics. 652. 123802–123802. 5 indexed citations

Wang, Busen, Zhe Zhang, Jinlong Zhang, et al.. (2023). Effects of SARS-CoV-2 Omicron BA.1 Spike Mutations on T-Cell Epitopes in Mice. Viruses. 15(3). 763–763. 3 indexed citations

Zhao, Zhenghao, Busen Wang, Shipo Wu, et al.. (2023). Regulated control of virus replication by 4-hydroxytamoxifen-induced splicing. Frontiers in Microbiology. 14. 1112580–1112580. 1 indexed citations

Wang, Busen, Jianhua Li, Shipo Wu, et al.. (2023). A seroepidemiological survey of adenovirus type 7 circulation among healthy adults in China and in Sierra Leone, West Africa. Frontiers in Public Health. 11. 1095343–1095343. 5 indexed citations

Wang, Busen, Shipo Wu, Zhe Zhang, et al.. (2022). Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs. Signal Transduction and Targeted Therapy. 7(1). 257–257. 6 indexed citations

Zhang, Zhe, Zhenghao Zhao, Yu Wang, et al.. (2022). Comparative immunogenicity analysis of intradermal versus intramuscular immunization with a recombinant human adenovirus type 5 vaccine against Ebola virus. Frontiers in Immunology. 13. 963049–963049. 15 indexed citations

Wang, Meirong, Ruihua Li, Yaohui Li, et al.. (2021). Construction and Immunological Evaluation of an Adenoviral Vector-Based Vaccine Candidate for Lassa Fever. Viruses. 13(3). 484–484. 8 indexed citations

10.

Wu, Shipo, Jianying Huang, Zhe Zhang, et al.. (2021). Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. The Lancet Infectious Diseases. 21(12). 1654–1664. 192 indexed citations breakdown →

11.

Wang, Busen, Jianhua Li, Shipo Wu, et al.. (2018). Seroepidemiological investigation of HAdV-4 infection among healthy adults in China and in Sierra Leone, West Africa. Emerging Microbes & Infections. 7(1). 1–10. 98 indexed citations

12.

Li, Yuhua, Ling Wang, Tao Zhu, et al.. (2018). Establishing China's National Standard for the Recombinant Adenovirus Type 5 Vector–Based Ebola Vaccine (Ad5-EBOV) Virus Titer. PubMed. 29(4). 226–232. 11 indexed citations

13.

Zhang, Zhe, Busen Wang, Shipo Wu, et al.. (2017). PD169316, a specific p38 inhibitor, shows antiviral activity against Enterovirus71. Virology. 508. 150–158. 16 indexed citations

14.

Li, Jingxin, Lihua Hou, Fanyue Meng, et al.. (2016). Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet Global Health. 5(3). e324–e334. 77 indexed citations

15.

Zhu, Fengcai, Lihua Hou, Jingxin Li, et al.. (2015). Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet. 385(9984). 2272–2279. 120 indexed citations

16.

Liu, Ying, Zhe Zhang, Xinghui Zhao, et al.. (2014). Enterovirus 71 Inhibits Cellular Type I Interferon Signaling by Downregulating JAK1 Protein Expression. Viral Immunology. 27(6). 267–276. 35 indexed citations

17.

Dong, Lei, Xiaopeng Zhang, Jun Ren, et al.. (2013). Human Prostate Stem Cell Antigen and HSP70 Fusion Protein Vaccine Inhibits Prostate Stem Cell Antigen-Expressing Tumor Growth in Mice. Cancer Biotherapy and Radiopharmaceuticals. 28(5). 391–397. 5 indexed citations

18.

Wu, Shipo, Lihua Hou, Wei Wei, et al.. (2012). Novel thermal-sensitive hydrogel enhances both humoral and cell-mediated immune responses by intranasal vaccine delivery. European Journal of Pharmaceutics and Biopharmaceutics. 81(3). 486–497. 47 indexed citations

19.

Song, Xiaohong, Ling Fu, Shipo Wu, et al.. (2011). Antiviral Potential of Exogenous Human Omega Interferon to Inhibit Pandemic 2009 A (H1N1) Influenza Virus. Viral Immunology. 24(5). 369–374. 10 indexed citations

20.

Yin, Ying, Hao Li, Shipo Wu, et al.. (2011). Hepatitis B virus core particles displaying Mycobacterium tuberculosis antigen ESAT-6 enhance ESAT-6-specific immune responses. Vaccine. 29(34). 5645–5651. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact